Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBO-154 in Advanced Solid Tumors
NCT07042100Phase 1Recruiting
- Sponsor
- Sun Pharma
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of SBO-154 in solid tumor, sponsored by Sun Pharma. Primary endpoints: Dose-Limiting Toxicities at 3 weeks, Serious Adverse Events and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
SBO-154
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07042100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07042100.